Peter Valent (2011) “Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities”, Haematologica. Pavia, Italy, 96(10), pp. 1395-1397. doi: 10.3324/haematol.2011.052076.